Danielle Mrozienski, APRN
Family · Casselberry, FLNPI 1164829545
Payments from drug & device makers
Across 65 payments — averaging $25.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$160
- UCB, Inc.$151
- AstraZeneca$126
- Neurocrine Biosciences, Inc.$120
- MDD US Operations, LLC$104
- Novo Nordisk$82
- plus $908 from 24 others
What the payments were for
- Food & beverage$1,651100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 4 | $160 |
| UCB, Inc. | 6 | $151 |
| AstraZeneca | 7 | $126 |
| Neurocrine Biosciences, Inc. | 1 | $120 |
| MDD US Operations, LLC | 1 | $104 |
| Novo Nordisk | 4 | $82 |
| Biogen | 3 | $79 |
| Merz Pharmaceuticals, LLC | 3 | $77 |
| Pfizer | 4 | $77 |
| Bayer | 3 | $68 |
| Neurelis, Inc. | 3 | $66 |
| Acadia Pharmaceuticals Inc | 2 | $45 |
| Lilly USA, LLC | 2 | $42 |
| C2n Diagnostics, LLC | 2 | $40 |
| Catalyst Pharmaceuticals, Inc. | 2 | $40 |
| AbbVie | 2 | $40 |
| Aucta Pharmaceuticals, Inc. | 3 | $35 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Jazz Pharmaceuticals Inc. | 1 | $31 |
| Boehringer Ingelheim | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Merck | 1 | $26 |
| Impel Pharmaceuticals LLC | 1 | $24 |
| Lundbeck LLC | 1 | $24 |
| GSK | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| SK Life Science, Inc. | 1 | $20 |
| Amgen | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,651 in reported general payments places this provider in the 75th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $34,735 |
| MounjaroTirzepatide | 27 | $28,478 |
| EliquisApixaban | 16 | $21,260 |
| OzempicSemaglutide | 18 | $20,087 |
| JardianceEmpagliflozin | 14 | $16,204 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $3,398 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 96 | $2,886 |
| Celecoxib | 20 | $2,094 |
| Levothyroxine Sodium | 60 | $990 |
| Diclofenac Sodium | 52 | $973 |
| Hydralazine Hcl | 32 | $916 |
| Atorvastatin Calcium | 79 | $661 |
| Gabapentin | 43 | $652 |
| Baclofen | 54 | $633 |
| Fluticasone Propionate | 62 | $568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $21 | $34,73534 claims |
| Lilly USA, LLCMounjaro | $42 | $28,47827 claims |
| PfizerEliquis | $77 | $21,26016 claims |
| Novo NordiskOzempic | $82 | $20,08718 claims |
| Boehringer IngelheimJardiance | $27 | $16,20414 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $99060 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 14,618 family providers in Florida.
Other family in Casselberry
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.